Introduction: The reported prevalence of ALK receptor tyrosine kinase gene (ALK) rearrangement in NSCLC ranges from 2% to 7%. The primary standard diagnostic method is fluorescence in situ hybridization (FISH). Recently, immunohistochemistry (IHC) has also proved to be a reproducible and sensitive technique. Reverse-transcriptase polymerase chain reaction (RT-PCR) has also been advocated, and most recently, the advent of targeted next-generation sequencing (NGS) for ALK and other fusions has become possible. This study compares anaplastic lymphoma kinase (ALK) evaluation with all four techniques in resected NSCLC from the large European Thoracic Oncology Platform Lungscape cohort.
ABSTRACT
Introduction: The reported prevalence of ALK receptor tyrosine kinase gene (ALK) rearrangement in NSCLC ranges from 2% to 7%. The primary standard diagnostic method is fluorescence in situ hybridization (FISH). Recently, immunohistochemistry (IHC) has also proved to be a reproducible and sensitive technique. Reverse-transcriptase polymerase chain reaction (RT-PCR) has also been advocated, and most recently, the advent of targeted next-generation sequencing (NGS) for ALK and other fusions has become possible. This study compares anaplastic lymphoma kinase (ALK) evaluation with all four techniques in resected NSCLC from the large European Thoracic Oncology Platform Lungscape cohort.
Methods: A total of 96 cases from the European Thoracic Oncology Platform Lungscape iBiobank, with any ALK immunoreactivity were examined by FISH, central RT-PCR, and NGS. An H-score higher than 120 defines IHC positivity. RNA was extracted from the same formalin-fixed, paraffin-embedded tissues. For RT-PCR, primers covered the most frequent ALK translocations. For NGS, the Oncomine Solid Tumour Fusion Transcript Kit (Thermo Fisher Scientific, Waltham, MA) was used. The concordance was assessed using the Cohen k coefficient (two-sided a 5%).
Results: NGS provided results for 77 of the 95 cases tested (81.1%), whereas RT-PCR provided results for 77 of 96 (80.2%). Concordance occurred in 55 cases of the 60 cases tested with all four methods (43 ALK negative and 12 ALK positive). Using ALK copositivity for IHC and FISH as the criterion standard, we derived a sensitivity for RT-PCR/NGS of 70.0%/85.0%, with a specificity of 87.1%/79.0%. When either RT-PCR or NGS was combined with IHC, the sensitivity remained the same, whereas the specificity increased to 88.7% and 83.9% respectively.
Conclusion: NGS evaluation with the Oncomine Solid Tumour
Fusion transcript kit and RT-PCR proved to have high sensitivity and specificity, advocating their use in routine practice. For maximal sensitivity and specificity, ALK status should be assessed by using two techniques and a third one in discordant cases. We therefore propose a customizable testing algorithm.
Introduction
Progress in understanding of the molecular mechanisms driving NSCLC has led to the development of new targeted drugs, mainly tyrosine kinase inhibitors (TKIs), and opened the field to new treatment strategies in molecularly selected cases. 1 Biomarkers have been identified to select patients eligible for these clinically validated therapies, including frontline application of gefitinib, 2 erlotinib, and afatinib for EGFR-mutated NSCLC, crizotinib therapy [3] [4] [5] [6] for ALK receptor tyrosine kinase gene (ALK)-or ROS1-rearranged NSCLC, and (recently) alectinib for ALK-rearranged NSCLC. 7 Around 2% to 7% of NSCLCs are characterized by the presence of an inversion or translocation of chromosome 2p involving the ALK gene, resulting in a transforming fusion gene echinoderm microtubule associated protein like 4 gene (EML4)-ALK, 8 which can be targeted with ALK TKIs. We previously reported the prevalence and clinical outcomes for resected stage I to III adenocarcinoma with ALK positivity assessed by immunohistochemistry (IHC) in the Lungscape patient cohort. 9 Reported prevalence of such alterations varies across studies as a consequence of both patient selection criteria and the specific detection methods used. 3, [10] [11] [12] Depending on the type of molecular alteration (mutation, translocation or amplification), a variety of techniques can be used to evaluate predictive biomarkers. Mutational status is usually assessed by polymerase chain reaction (PCR) and/or sequencing with a diversity of accepted techniques limited by the spectrum of PCR and sequencing methods available. In contrast, rearrangements including, but not limited to, ALK rearrangements can be identified with a wider range of techniques including fluorescence in situ hybridization (FISH), reverse-transcriptase PCR (RT-PCR), next-generation sequencing (NGS), or IHC. For each of these methods, both commercial kits and validated laboratory-developed tests may be used, subject to local regulations and practice.
Although RT-PCR was the first published method 8 for determining ALK status, FISH, a widely available technique for formalin-fixed, paraffin-embedded (FFPE) specimens known to preserve tissue architecture, has supplanted it. ALK FISH was approved as a companion diagnostic by the U.S. Food and Drug Administration. In the context of multiple retrospective comparative biomarker studies, IHC has proved to be a very sensitive technique for anaplastic lymphoma kinase (ALK) protein expression, which is usually absent from normal lung tissues. It has recently been adopted 6,13-17 as a primary screening method for detection of patients with ALK rearrangement and treatment selection.
This study compares ALK evaluation with multiple technologies, FISH, RT-PCR, and targeted NGS, in the Lungscape cohort by using any degree of ALK IHC positivity as a selection criterion.
We also reviewed literature and discussed the limitations and potential advantages inherent to each technique to refine and optimize diagnostic strategies.
Material and Methods
The research was conducted according to the Lungscape master and ALK subproject protocols with adherence to country-specific ethics, regulatory requirements, and Reporting Recommendations for Tumor Marker Prognostic Studies. 18 
Case Selection
This is a cohort study of surgically resected stage I to III NSCLC cases from the European Thoracic Oncology Platform Lungscape. 19 ALK IHC analysis was implemented in a large subset of the Lungscape cohort with FISH performed on IHC-positive cases and matched negative controls. RT-PCR and NGS were performed on all IHCpositive cases, irrespective of extent or intensity of staining.
For ALK FISH and IHC, all sites participated in an external quality assessment for the laboratory analyses, and all samples were analyzed at their site of origin, following the same methods.
IHC and FISH
ALK IHC using clone 5A4 antibody (Novocastra, Leica Biosystems, Buffalo Grove, IL) and the Novolink detection system (Leica Biosystems) and FISH using Vysis ALK break-apart FISH probe (Abbott Molecular, Des Plaines, IL) were performed and evaluated according to previously published methodology. 9 
RNA Extraction for RT-PCR and NGS
After macrodissection for tumor enrichment, RNA was extracted from unstained slides using the Qiagen RNeasy FFPE Kit (Qiagen, Hombrechtikon. Switzerland) according to producer instructions. RNA was quantified by Qubit Fluorimeter 2.0 (Invitrogen, Carlsbad, CA) Quant-iT RNA assay Kit (Invitrogen). RNA from the same extraction was used for both RT-PCR and NGS testing. RNA extraction details are provided in the Supplementary Methods.
RT-PCR
The obtained RNA was eluted by using 20 to 30 mL of water and RNasin Plus (final concentration w1%). Betaactin forward and reverse primers were used to amplify a region of 196 bp of the actin beta gene (ACTB) as an internal positive control. RT-PCR was performed starting from 50 ng of total RNA by using two PCR mixes (mix 1 and mix 2) including Superscript One-Step RT-PCR and Platinum Taq (Invitrogen) in a Primus 25 thermocycler (MWG-BIOTECH Europe, Ebersberg, Germany) with the following programs: initial RT reaction at 50 C for 30 minutes; 95 C for 2 minutes followed by PCR reaction (40 cycles) consisting of 95 C for 30 seconds, 57 C for 45 seconds, and 72 C for 1 minute and 15 seconds; and final elongation at 72 C for 10 minutes. EML4-ALK primers (see Supplementary Table 1 , which provides RT-PCR primer information) were used at a concentration of 10 rmol/mL and those for beta-actin were used at a concentration of 2 rmol/mL. Analysis of the obtained product was done by using capillary electrophoresis on QIAxcel with a QIAxcel DNA Screening Kit. All tests were performed in duplicate ( Fig. 1 ; NGS data visualization in Supplementary Fig 1) . Torrent Suite software, version 4.4.2, was used to remove low-quality reads, trim adapter dimers, and align to a reference genome (hg19). RNA fusion data were then uploaded to Ion Reporter 4.6 and analyzed by using the AmpliSeq RNA Lung Fusion v4.6 workflow.
Targeted NGS

Statistics
The concordance between the alternative methods was assessed through multiway tables. The statistical significance of paired associations was based on the Cohen k coefficient (two-sided a 5%). A waterfall plot was used to graphically compare the four methods. The sensitivity and specificity of each method were calculated (on cases with available results for IHC [H-score], FISH, and either RT-PCR or NGS) by using the combined result of IHC H-score and FISH as the criterion standard. True positive cases were those with a positive result by both methods (H-score >120 and FISH positivity).
Median RNA concentrations between groups of cases were compared on the basis of the nonparametric Wilcoxon test. Statistical analyses were performed with SAS software (version 9.3, SAS Inc., Cary NC) and R language for statistical computing (version 3.2.2, R Foundation for Statistical Computing, Vienna, Austria). 20 
Results
Study Cohort
From the 2709 cases registered in the Lungscape iBiobank, 1772 were screened for ALK by IHC. All patients selected for this study were considered ALK IHC-positive on the basis of IHC intensity scoring of 1þ and higher (N ¼ 96 [5.4%]; H-score was not available for four cases). Among them, 76 patients (79.2%) had adenocarcinoma, 13 (13.5%) had squamous cell carcinoma, four (4.2%) had large cell carcinoma, and three (3.1%) had combined (mixed) carcinoma.
IHC
All cases were at least focally positive for ALK by IHC, with variable maximum intensity: 1þ in 58 cases (60.4%), 2þ in 16 (16.7%), and 3þ in 22 (22.9%). As previously reported, 9 an H-score cutoff of 120 correlated with FISH status and was used to classify IHC as positive in the rest of the study. H-Score was retrieved from the Lungscape iBiobank database and was available for 92 cases of the 96 cases positive for ALK by IHC (four cases from a single center had missing H-scores). Twentythree cases (25%) had an H-score higher than 120 and 69 (75%) had an H-score of 120 or lower.
FISH
FISH results were available for 88 cases: 24 FISHpositive (27.3%) and 64 FISH-negative (72.7%) cases.
Tumor Cellularity and RNA Yield
The median tumor cellularity and RNA yield were 70% (range 10%-90%) and 47 ng/mL (range 9-300), respectively.
The median RNA concentration was significantly lower in cases in which RT-PCR failed than in cases in which RT-PCR was successfully implemented (34 versus 55 ng/mL [p ¼ 0.0056]), whereas no significant difference was found between groups of cases by NGS failure or success (p ¼ 0.17) (see Supplementary Table 3 , which shows RNA concentration by RT-PCR and NGS result).
RT-PCR
The assay was successful in 77 of the 96 cases analyzed (80.2%). In 19 cases in which no beta-actin could be co-amplified, RNA quality was considered as insufficient for result validation. ALK rearrangement was identified in 16 cases (20.8%). Translocations were characterized in 13 rearranged cases: V1 in five cases (38.5%), V2 in one (7.7%), and V3a/b in seven (53.8%).
NGS
The assay passed quality control and was initially successful in 90 of the 95 cases (94.7%) analyzed. A specific ALK rearrangement fusion partner transcript was initially identified in 15 cases (16.7%) and a 3 0 /5 0 imbalance value was assessed in cases in which no specific ALK rearrangement was detected (see Supplementary Fig. 2 , which shows imbalance scores against criterion standard assessment of positivity). The imbalance assay is a method to screen for ALK gene (or other) rearrangements by assessing the ratio of 3 0 to 5 0 amplicon reads standardized against all control gene reads. Essentially, the imbalance assay gives an indication of the likelihood that a fusion is present. When a rearrangement is present, there is preferential loss of the Strong evidence of imbalance (score 0.010) was observed in six cases, uncertain evidence (score in 0.001--0.010) in 11 cases, and no evidence (score 0.001) in 56. Cases with strong evidence of imbalance were considered highly likely to be ALK NGS-positive but suggesting additional validation by using another technology. Cases with uncertain evidence of imbalance were considered failed assays because the software could not determine positivity or negativity. Thus, we finally proceeded to further analyses with 77 available results (an 81.1% success rate), with 21 NGS positive (27.3%) and 56 NGS negative (72.7%).
Of the 15 cases with characterized ALK translocations, V1 was found in four cases (26.7%), V2 in one (6.7%), and V3a/b in 10 (66.7%). Seven cases had more than one isoform: three cases had two isoforms and four cases had three. In six cases with strong evidence of imbalance no specific translocations could be identified. Supplementary Table 4 and Supplementary Fig. 3 ).
Concordance of Methodologies
IHC and FISH. Concordance of IHC (H-score cutoff) with FISH was evaluated in 87 cases: 84 cases (97%) were concordant (22 positive and 62 negative) and three were discordant (one FISH-negative with an H-score >120, two FISH-positive with H-score 120) with a k coefficient of 0.91 (p < 0.001 [data not shown]).
RT-PCR. Paired concordance of RT-PCR with IHC, Hscore, and FISH was evaluated in 77, 73, and 73 cases, respectively (Table 1) . RT-PCR was highly concordant with an H-score and FISH with a k coefficient of 0.88 and 0.85, respectively (p < 0.001 for all). Within the RT-PCRpositive group, 93.8% are strongly IHC positive (2þ or 3þ) with an H-score higher than 120 and FISH positivity.
Joint concordance of RT-PCR with IHC (H-score) and FISH was evaluated in 72 cases (Table 2) , of which 67 (93.1%) had complete agreement among all three methods.
NGS. Paired concordance of NGS with IHC, H-score, FISH, and RT-PCR was evaluated in 77, 73, 71, and 65 cases (see Table 1 ). NGS was highly concordant with H-score, FISH, and RT-PCR, with k coefficients of 0.90, 0.86, and 0.91, respectively (p < 0.001 for all). In the NGS-positive group, 85.7% are strongly IHC positive (2þ or 3þ) with an H-score higher than 120 and FISH positivity and 87.5% are RT-PCR-positive.
Joint concordance of NGS with both IHC (H-score) and FISH results was evaluated in 70 cases (see Table 2 ). Agreement of the three methods was achieved in 67 cases (95.8%).
Joint Comparison of All Methods. Joint concordance of all four methods was evaluated in 60 cases (Table 3) . Agreement of all methods (H-score, FISH, RT-PCR, NGS) was achieved in 55 cases (91.7%), of which 12 were positive (75.0% of all 16 NGS-positive) and 43 were negative (97.7% of all 44 NGS-negative).
The sensitivity and specificity of each stand-alone method and of the combination of IHC with RT-PCR or NGS is based on 82 cases with available results for IHC, FISH, and either RT-PCR or NGS. The criterion standard was determined by the combined result of IHC (H-score >120) and FISH (see Supplementary Table 5 , which shows the sensitivity and specificity scores of the four methods). This corresponded to 70.0% and 85.0% sensitivity for RT-PCR/NGS, with 87.1% and 79.0% specificity, respectively. IHC combined with either RT-PCR or NGS resulted in the same sensitivity, whereas the specificity increased to 88.7% and 83.9%, respectively. When only the subset of 60 cases with available results in all four methods were used, NGS had higher sensitivity and lower specificity than RT-PCR (100.0% IHC intensity (1þ, 2þ, or 3þ) .
versus 92.3% and 93.6% versus 95.7%, respectively) (see Supplementary Table 6 , showing sensitivity and specificity scores of the four methods).
Discussion
We previously investigated the prevalence of ALK positivity by using IHC confirmed by FISH and compared IHC with FISH for detection of ALK positivity in resected lung adenocarcinoma by using the European Thoracic Oncology Platform Lungscape iBiobank. 9 The current study is, to the best of our knowledge, the first and largest study to evaluate ALK status with the four most common methodologies currently in use, namely IHC,
FISH, RT-PCR, and NGS in predominantly European patients with resected stage I to III NSCLC.
We used any degree of ALK IHC positivity as the primary selection criterion for further parallel FISH, RT-PCR, and NGS analysis, uniquely allowing us to investigate all four techniques on the same samples, allowing direct comparisons.
If concordance of any two techniques is considered true positivity instead of the concordance of IHC and FISH being defined as the criterion standard, our study confirms that none of the techniques exhibits 100% sensitivity and specificity. This finding affects the accuracy of treatment strategy decisions and quality of clinical management of individual patients if only one assay is used. IHC can result in both false-positive and falsenegative results. The two main explanations for false negativity are a failed staining technique-this should be identified in the analytical process, provided a validated external control is used-or preanalytical tissue fixation problems resulting in epitope alteration. Those cases can go unnoticed in the absence of ALK expression in normal tissues as an internal control. IHC results may vary by the clone and technique used, although they are usually considered equivalent when appropriately validated and scored. In a recent large series comparing the two most common antibodies, clones 5A4 and D5F3, by using FISH, sensitivity and specificity were 87% and 92% and 89 and 76% respectively. 21 On the basis of our previous work, 9 we had proposed an H-score cutoff higher than120 as giving the highest probability for concordance with matched ALK FISH positivity. False IHCpositive cases are rarely encountered if one uses an H-score higher than120. False positivity can also be attributed to technical/interpretative issues (background being interpreted as positivity) or ALK amplification, as recently suggested. 22 Among the 1772 cases tested, 104 showed at least focal IHC positivity (maximum IHC score 1þ). Only one IHC-positive case was FISH negative and is discussed in the following paragraph. With the inclusion criteria for this study being any degree of ALK IHC positivity, true sensitivity cannot be determined, as the remaining IHC (0þ) cases were not tested by NGS or RT-PCR.
FISH can also provide both false-positive and falsenegative results. 22 ALK FISH assay reading is subject to misinterpretation, requiring an experienced pathologist for accurate evaluation. Positivity versus negativity is determined by the presence of split signals in more or less than 15% of cells. 23 Most of the false-negative/falsepositive interpretations appear to occur when the count is around this threshold and in up to 20% of cells. 21, 22 Inadequate material or failed technique can be easily identified when FISH results are read by using internal validation of hybridization quality and presence of appropriate fluorescent probes signals. FISH remains a robust technique, with a success rate reported in up to 98% to 99% of cases. 21 Two cases in our series were suggestive of FISH positivity, with an H-score of 120 or lower (one case with RT-PCR and NGS also positive and one case with a FISH split signal in 16% of cells but RT-PCR and NGS negativity). Another case was FISH negative (split signal in 13% of cells) with an H-score higher than 120 and RT-PCR and NGS positivity. For the last two cases described (with FISH split signals just above and below 15%), the other three techniques (IHC, RT-PCR, and NGS) were concordant among them but contradictory to FISH results, illustrating the 15% threshold limitation.
In the break-apart designed FISH assay, a positive result does not imply that the fusion partner gene is EML4, and virtually any type of ALK rearrangement/ partner could be identified by this technique, leading to or preventing ALK gene transcription. A positive FISH result as a predictive marker for targeted therapy is thus theoretically not always guaranteed.
RT-PCR provides mainly false-negative results in discordant cases. The limitation of this very specific technique resides in its ability to detect only known translocations and, more specifically, those that the assay was designed to detect (variants V1 to V8 [as defined by the PCR primer]), thus conferring to this technique very high specificity but lower sensitivity. Another limitation is linked to the fact that this is an RNA-based assay. Its success relies on RNA quality and thus depends on preanalytical factors. Prolonged ischemia or inadequate fixation can result in RNA degradation. In our series two cases were classified as RT-PCR-negative with FISH and IHC-positive, potentially illustrating this issue. One of these cases failed NGS (uncertain imbalance evidence) and the other was NGS positive (strong imbalance evidence), meaning they represent probable translocations not covered by both assays. Table 3 . ALK NGS result according to RT-PCR result, ALK FISH status, and H-score levels utilizing the imbalance scores
NGS Status
H-Score>120
H-score120
All patients NGS, also an RNA-based assay, has limitations similar to those of RT-PCR regarding primer design and RNA quality; nevertheless, it covers almost all variants described to date, including partners other than EML-4 (see Supplementary Table 2 ). Our data show that its success rate for passing quality control assessment with the same RNA is approximately equal (81% versus 80% success rate [see Supplementary Table 3 , which shows RNA concentration by RT-PCR and NGS result]) to that with RT-PCR. The limitation of detecting only known translocations can be overcome by using imbalance score as described earlier in this article and appropriately validating high probability imbalance scores by using an orthogonal assessment. This orthogonal validation is of great importance, as shown in one of our cases with a "positive" imbalance score but classified as negative with the three other techniques.
Assessing the sensitivity and specificity of each assay is challenging because defining a criterion standard for ALK status is problematic, as exceptional cases occur. Our reasoned approach was that the best approximation of a criterion standard would be concordance of the most widely used techniques, IHC (H-score cutoff >120) and FISH, allowing the most robust comparison with RT-PCR and NGS. On that basis, 22 cases were considered as criterion standard ALK-positive/rearranged.
Whereas the sensitivities of NGS as a stand-alone method or used in combination with IHC in comparison with the criterion standard (H-score >120 and FISHpositiveity) are high 85% for both, specificities are lower at 79% and 84%, respectively. However, the true sensitivity of NGS as a primary ALK screening methodology cannot be inferred from these data because the analysis was limited to cases preselected from the entire Lungscape cohort by IHC. Limitations to this approach are discussed later in this article.
In our study we did not find superiority of RT-PCR over FISH as reported by other authors 24, 25 or NGS over FISH 26 as suggested in a recent study with a limited number of centers. If any of the assays are successful, their sensitivity and specificities appear to be almost equivalent if taken individually.
Variants Characterization
One of the added values of RT-PCR and NGS is their ability to characterize the type/variant of ALK translocation. Interestingly, 10 of 21 NGS-positive cases corresponded to Variant 3a/b, representing 66.7% of the 15 characterized ALK-positive cases. According to the data available in the literature, this variant is usually found in around 30% of ALK-rearranged cases. [27] [28] [29] Despite the limited number of cases in our study, this finding might suggest that this variant is more frequently linked with lower stage (stage I-III) tumors and/or the European population than with the Japanese population. 30 Variants were concordant between NGS and RT-PCR.
Treatment outcome and duration of response vary widely in patients treated with crizotinib. The significance of the ALK variants in clinical practice is not clear yet and remains controversial, although in vitro studies suggest variable degrees of crizotinib efficacy depending on the variant present. 31, 32 Moreover, a differential duration of response to crizotinib was suggested according to the ALK translocation variants, with V1/2 being characterized by a higher objective response rate and longer progressionfree survival. 30, 33 Characterizing the type of translocation is necessary for the investigation of its relevance as a better predictor of response and might become standard in the future in clinical practice, 34, 35 giving an advantage to NGS or RT-PCR over IHC and FISH.
The multiplex method for fusion detection presented takes the approach of using a literature-based PCR library design, meaning that all fusion partners are identified before assay design and the assay is appropriately focused on these most common variants. The advantage of this approach is that it will function with the small amounts of RNA typical of clinical lung cancer samples. Hybridization-based methods, which can be designed to detect novel fusion partners, typically require higher RNA input volumes and are assumed to be less likely to return a result when presented with a small sample. A more recent method known as anchored multiplex PCR would allow the identification of novel fusion partners and function with a relatively small input RNA volume. 36 Whereas the Ampliseq-based method does not specifically identify novel fusion partners, the 3 0 /5 0 imbalance score functions as a fail-safe to highlight cases in which a novel fusion might be present in the sample.
Limitations
Sensitivity analysis of ALK IHC positivity is precluded by the use of IHC positivity as an inclusion criterion, but previously published data 37 suggest that it is very high. In our series, the proportion of cases with failed technique is high compared with the literature, probably because of the use of archival material from various centers using variable fixation protocols. 38 According to the literature, the variability of discrepancies is higher when pooling data and materials from multiple sites, 21 probably because of the use of archival material without standardized fixation protocols. 38 We also observed such an effect in this study, with the RT-PCR failure rate being higher than 87% for material originating from specific centres, representing more than 35% of failed assays (data not shown). The failure rates (19.8% and 18.9% for RT-PCR and NGS, respectively, in this study) might be much lower in a controlled setting, when adequate fixation is used as shown in the literature 38 .
Thus, RT-PCR and mostly NGS are routinely possible and have the advantage that failed assays because of inappropriate RNA quality can be identified.
Costs
Although not formally assessed in this study, cost is clearly relevant to this discussion. Molecular testing, including at least EGFR and ALK analysis, is now routinely undertaken in advanced nonsquamous NSCLC. 6, 39 Health system structures, testing recommendations, and resources vary from country to country, as do the costs of each test. Thus, the best testing algorithm, as defined by the highest sensitivity and specificity for ALK status, might not be the most cost-effective, and consequently, it might be unaffordable in specific countries. Among the four techniques discussed, IHC is the least complex and least expensive, followed by RT-PCR and FISH. 40 The costs of NGS-based assays remain higher and require sophisticated instrumentation and interpretive expertise but generate more genetic data than any other assay. Besides providing the variant and imbalance score, they also provide information about other relevant and potentially targetable molecular alterations (ret proto-oncogene gene [RET], ROS1, and neurotrophic receptor tyrosine kinase 1 gene [NTRK1] translocation and EGFR, BRAF, and erb-b2 receptor tyrosine kinase 2 gene [HER2] mutations, depending on the assay used). A single RET-rearranged case was identified among the patients tested.
Conclusion
Our study confirms high sensitivity and specificity for FISH, RT-PCR, and NGS with use of the Oncomine Solid Tumor Fusion transcript kit for evaluation of ALK status. These findings support the feasibility of NGS-based (and RT-PCR-based) approaches on FFPE samples in diagnostic routine for ALK detection, as long as standardized and adequate preanalalytic handling of the samples is performed to guarantee good RNA quality.
IHC is currently approved for selecting therapy without orthogonal testing. It is an inexpensive, easy to set up and interpret technique and is therefore usually recommended/used for initial screening to eliminate negative cases. However, it seems intuitive that as multiplex testing become more widely used, and information about fusion variants proves to be relevant, NGS will become the primary test and any fusion gene positivity will need confirmation by an orthogonal test.
Every technique has limitations; thus, if maximal sensitivity and specificity for detection of ALK rearrangement is sought, confirmation of ALK status by using at least two techniques is mandatory, adding a third one if cases are discordant (Supplementary Table 7 for reclassified cases). Nevertheless, depending on local skills, equipment access, and costs, a variety of validated approaches will be developed as proposed in our algorithm (Fig. 3) . This significantly influences existing testing paradigms and has clear clinical and economic impact. Proposed testing algorithm for anaplastic lymphoma kinase (ALK) evaluation using different techniques for maximal sensitivity and specificity, starting with a double-testing, including immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) or RNA-based assay reverse-transcriptase polymerase chain reaction (RT-PCR)/next-generation sequencing (NGS), followed by a third assay in discordant cases (RNA-based assay if FISH was performed and vice versa). *IHC positivity as defined for each antibody for the example of an H-Score higher than 120 for the clone 5A4 antibody from Novocastra.
